A significant shift in U.S. environmental regulation is unfolding as the Environmental Protection Agency (EPA) moves to relax certain limits on per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals.” These substances are linked to a range of serious health conditions, including cancer, reproductive issues, and immune system disruption.
The EPA’s decision marks a rollback of strict limits introduced under the Biden administration. While two of the most widely studied PFAS, PFOA and PFOS, will remain tightly regulated at 4 parts per trillion, the agency plans to rescind national limits on four additional PFAS variants: GenX, PFHxS, PFNA, and PFBS. The compliance deadline for water utilities has also been extended by two years.
A balancing act: Flexibility vs. health protection
The EPA describes the move as “common-sense flexibility” intended to ease the burden on smaller, rural water systems. However, health and environmental experts warn that delaying or diluting regulation on PFAS risks exposing millions of Americans to harmful chemicals for longer than necessary. Some advocacy groups have gone so far as to call the changes unlawful, citing strong scientific consensus on the risks associated with PFAS exposure.
This rollback reflects a broader policy pivot. The EPA, now led by Administrator Lee Zeldin, has taken steps to reverse or pause a number of environmental protections in favour of economic considerations and regulatory streamlining.
PFAS: Ubiquity and long-term impact
PFAS are synthetic compounds used in a range of consumer and industrial products, from non-stick cookware and food packaging to firefighting foams. They are resistant to breaking down in the environment, which is why they are often referred to as “forever chemicals.” Once in the water supply, they can accumulate in the human body over time, posing long-term health risks.
Even at very low concentrations, exposure to PFAS has been linked to adverse health outcomes, including:
-
Increased risk of certain cancers
-
Liver and kidney damage
-
Hormonal and immune system disruption
-
Developmental effects in infants and children
Industry implications: Risk, responsibility, and resilience
For organisations across infrastructure, utilities, manufacturing, and healthcare, the regulatory shift presents both risk and opportunity. While the easing of rules may reduce near-term compliance costs, the reputational and public health risks of inaction are significant.
Now is a critical time for leaders to:
-
Stay ahead of evolving standards. Anticipate future state-level or international regulations, which may be stricter than federal U.S. guidelines.
-
Invest in proven mitigation technologies. Granular activated carbon, ion-exchange systems, and reverse osmosis are already helping remove PFAS effectively in many regions.
-
Engage transparently with stakeholders. Clear communication with communities, customers, and employees builds trust and supports long-term licence to operate.
Looking ahead
The regulatory landscape for PFAS remains dynamic. While the federal rollback may offer some operational breathing room, the direction of travel, both scientifically and politically, points toward tighter controls over time.
Proactive action remains the most resilient strategy.